Lilly and existing partner AstraZeneca have agreed to co-develop a Phase I immunotherapy targeting neurotoxic amyloid-β peptide, MEDI1814, for Alzheimer's disease (AD). According to the deal, Lilly paid US$30 M upfront to AstraZeneca. The deal is propelled by the major setback faced by Lilly whereby its AD drug, solanezumab, failed to meet the primary endpoint in the Phase III (EXPEDITION3) trial and the company consequently dropped plans to pursue regulatory submission of the drug. The deal strengthens the relationship between AstraZeneca and Lilly, which have a prior collaboration for a BACE inhibitor, AZD3293.